Cosentyx Receives FDA Approval for New Indication to Treat Active Non-Radiographic Axial Spondyloarthritis

EAST HANOVER, N.J., June 16, 2020 /PRNewswire/ -- Novartis, a leader in rheumatology and immuno-dermatology, today announced that the US Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) for the treatment of active...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news